Stocktoria
Seres Therapeutics, Inc. MCRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-06-26
Seres Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $789,000 | $0 | $0 | $7.1M | $144.9M |
| R&D expense | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M | -$65.6M |
| EPS (diluted) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 |
| Operating cash flow | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M |
| Cash & equivalents | $45.8M | $30.8M | $128.0M | $163.0M | $180.0M |
| Inventory | — | — | $29.6M | $0 | — |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M |
| Shareholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M |
Source: SEC EDGAR filings · CIK 0001609809 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.